ICAM

ICAM
Name	Intercellular adhesion molecule

ICAM

ICAM is a family of cell-surface proteins that mediate leukocyte adhesion and transmigration, participating in innate and adaptive immune responses as well as vascular biology. First characterized in studies linking endothelium-leukocyte interactions, ICAM members interact with integrins and other receptors to coordinate cell trafficking during inflammation, infection, and tissue repair. Research on ICAM spans molecular biology, immunology, and clinical medicine, connecting work at institutions such as Harvard University, Stanford University, Pasteur Institute, National Institutes of Health, and Mayo Clinic.

Introduction

ICAM proteins were identified in the context of leukocyte adhesion to endothelium during investigations involving investigators at Salk Institute and Johns Hopkins University. Early functional assays used cells from patients at Massachusetts General Hospital and model systems developed at Cold Spring Harbor Laboratory and Max Planck Society. ICAMs bind integrins such as LFA-1 (CD11a/CD18), discovered in experiments influenced by research at University of California, San Francisco and Imperial College London. Structural biology efforts at European Molecular Biology Laboratory and Weizmann Institute of Science clarified domain arrangements, while clinical correlations emerged from cohorts at Cleveland Clinic and Karolinska Institutet.

Molecular Structure and Isoforms

ICAM family members share immunoglobulin-like domains and transmembrane regions characterized by studies using crystallography at Brookhaven National Laboratory and Diamond Light Source. Key isoforms include ICAM-1, ICAM-2, ICAM-3, and ICAM-5, each encoded by genes mapped in genomic projects involving Human Genome Project partners such as Wellcome Trust Sanger Institute and Broad Institute. Isoform diversity arises from alternative splicing and post-translational modifications, processes investigated by teams at John Innes Centre and Cold Spring Harbor Laboratory. Comparative genomics across species including Mus musculus, Danio rerio, and Drosophila melanogaster informed evolutionary analyses published by researchers at University of Cambridge and Yale University.

Expression and Regulation

ICAM expression is regulated by cytokines like tumor necrosis factor-alpha and interleukin-1 through transcription factors characterized at University of Chicago and Columbia University. Endothelial and immune cell expression patterns were profiled in transcriptomic studies from consortia including ENCODE and GTEx. Epigenetic and signaling modulators such as NF-κB and MAPK pathways were delineated in laboratories at MIT, ETH Zurich, and University of California, Berkeley. Viral infections studied at Centers for Disease Control and Prevention and Oswaldo Cruz Foundation modulate ICAM levels, a phenomenon explored in work on human rhinovirus, HIV-1, and influenza A virus.

Biological Functions

ICAM proteins mediate adhesion of leukocytes to endothelium, facilitating extravasation in models established at Albert Einstein College of Medicine and University of Pennsylvania. ICAM-integrin interactions contribute to immunological synapse formation in studies from Rockefeller University and Fred Hutchinson Cancer Center. Neural isoforms like ICAM-5 influence synaptic adhesion in research contexts at Max Planck Institute for Brain Research and University College London. Roles in platelet interactions and hemostasis were examined in collaborations involving St. Jude Children's Research Hospital and Royal College of Surgeons.

Role in Disease

Aberrant ICAM expression is implicated in inflammatory conditions such as rheumatoid arthritis, multiple sclerosis, and psoriasis in clinical studies from Johns Hopkins Hospital and Mount Sinai Hospital. Elevated ICAM levels correlate with cardiovascular events in cohorts from Framingham Heart Study and studies at Johns Hopkins Bloomberg School of Public Health. ICAM-mediated entry or modulation is relevant to infections by human rhinovirus and other pathogens investigated at Institut Pasteur and NIAID. Cancer-related changes in ICAM expression affect metastasis and tumor immune microenvironment in research from Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center.

Clinical and Therapeutic Applications

Targeting ICAM interactions has been pursued with monoclonal antibodies developed in collaboration with biotech firms and academic spinouts from University of Pennsylvania and University of Oxford. Anti-adhesion strategies were tested in clinical trials overseen by regulatory agencies such as Food and Drug Administration and European Medicines Agency. Diagnostic assays measuring soluble ICAM are used in studies coordinated by Cleveland Clinic and Mount Sinai, while gene-expression signatures including ICAM components inform precision medicine programs at MD Anderson Cancer Center and Kaiser Permanente.

Experimental Methods and Assays

Key experimental approaches include flow cytometry protocols refined at Stanford University School of Medicine and Addenbrooke's Hospital, immunoprecipitation methods from MRC Laboratory of Molecular Biology, and live-cell imaging done at Janelia Research Campus. Structural determination employed cryo-EM facilities at HHMI and synchrotrons like European Synchrotron Radiation Facility. Animal models from The Jackson Laboratory and nonhuman primate studies coordinated by Yerkes National Primate Research Center support mechanistic work, while high-throughput screening platforms at Scripps Research enable therapeutic discovery.

Category:Cell adhesion molecules